Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

WJ Burke, I Gergel, A Bose - Journal of Clinical Psychiatry, 2002 - psychiatrist.com
Background: Escitalopram is the single isomer responsible for the serotonin reuptake inhibition
produced by the racemic antidepressant citalopram. The present randomized, double-…

Escitalopram in the treatment of generalized anxiety disorder: Double‐blind, placebo controlled, flexible‐dose study

JRT Davidson, A Bose, A Korotzer… - Depression and …, 2004 - Wiley Online Library
Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with
depression, panic disorder, and social anxiety disorder. This study was designed to evaluate …

[HTML][HTML] A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia

…, Y Du, J Zummo, L Corey, A Bose… - The Journal of clinical …, 2015 - psychiatrist.com
Objective: This study evaluated the efficacy, safety, and tolerability of aripiprazole lauroxil, a
novel long-acting injectable atypical antipsychotic, for the treatment of schizophrenia. Method…

Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo …

GM Asnis, A Bose, CP Gommoll, C Chen… - J Clin …, 2013 - psychiatrist.com
Objective: This phase 3, randomized, double-blind, placebo-controlled study evaluated the
efficacy and tolerability of fixed-dose levomilnacipran sustained release (SR) compared with …

A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder

RJ Bielski, A Bose, CC Chang - Annals of Clinical Psychiatry, 2005 - Taylor & Francis
Background. This study compared the efficacy and tolerability of escitalopram, a newer SSRI,
with paroxetine in the treatment of generalized anxiety disorder (GAD). Methods. Patients …

Escitalopram continuation treatment prevents relapse of depressive episodes

MH Rapaport, A Bose, H Zheng - Journal of Clinical Psychiatry, 2004 - psychiatrist.com
Background: Current guidelines for antidepressant use recommend 4 to 6 months of
continuation treatment to prevent relapse of depression following symptom resolution. This study …

Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials

WK Goodman, A Bose, Q Wang - Journal of Affective Disorders, 2005 - Elsevier
BACKGROUND: Escitalopram 10 mg/day is an effective and well-tolerated antidepressant.
Three randomized controlled trials recently evaluated the safety and efficacy of escitalopram …

[HTML][HTML] A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder

A Sambunaris, A Bose, CP Gommoll… - Journal of Clinical …, 2014 - journals.lww.com
Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine
reuptake inhibitor; an extended-release (ER) formulation allows for once-daily dosing. …

Original Research Efficacy and Safety of Levomilnacipran Sustained Release in

SA Montgomery, L Mansuy, A Ruth, A Bose, H Li… - J Clin …, 2013 - psychiatrist.com
Objective: To investigate the efficacy and safety of levomilnacipran sustained release (SR),
an antidepressant candidate in late-stage development, in major depressive disorder (MDD). …

Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial

RL Findling, A Robb, A Bose - Journal of child and adolescent …, 2013 - liebertpub.com
Objective: The purpose of this study was to evaluate the extended efficacy, safety, and tolerability
of escitalopram relative to placebo in adolescents with major depressive disorder (MDD…